SARC041: Establishing CDK4/6 Inhibition as a New Treatment Option in Dedifferentiated Liposarcoma

Dedifferentiated liposarcoma (DDLPS) remains one of the most challenging soft tissue sarcomas to treat in the advanced setting. Although surgery remains the cornerstone of therapy for localized disease, systemic treatment options for recurrent or metastatic DDLPS have historically provided limited clinical benefit. Recently presented at the 2026 American Society of Clinical Oncology Annual Meeting, the SARC041 trial demonstrates a benefit in PFS by the targeted inhibition of CDK4/6 with abemaciclib compared with placebo. These findings may reshape treatment sequencing for patients with advanced DDLPS.

Historical Outcomes With Systemic Therapy in Advanced DDLPS

Historically, systemic therapies for DDLPS have demonstrated modest efficacy. First-line anthracycline-based chemotherapy remains the standard option for patients requiring rapid tumor reduction. In intra-abdominal well-differentiated/dedifferentiated liposarcoma (WD/DDLPS), single-agent doxorubicin achieves a median PFS of approximately 4 months with an ORR of only 9%. The addition of ifosfamide improves response rates to approximately 13% to 15% but at the cost of substantially increased toxicity. 

Later-line cytotoxic agents have similarly demonstrated limited activity. Gemcitabine plus docetaxel achieves an ORR of approximately 10% with a median PFS of 9.2 months, while eribulin improved overall survival (OS) by approximately 2 months compared with dacarbazine despite nearly identical PFS (2 months vs 2.1 months). Trabectedin similarly demonstrated an improvement in PFS compared with dacarbazine (2.2 months vs 1.9 months), but not survival. Immunotherapy has also produced relatively modest outcomes, with pembrolizumab as well as combination nivolumab plus ipilimumab achieving an ORR of approximately 14% to 20% and median PFS of 5.5 months to 5.8 months (Figure 1).

Figure 1. Historical Systemic Therapy Outcomes in Advanced DDLPS

Biologic Rationale for CDK4/6 Inhibition

The rationale for targeting CDK4 in DDLPS is particularly compelling from a biologic standpoint. More than 90% of WD/DDLPS tumors harbor amplification of the CDK4 gene, making it one of the defining molecular abnormalities of the disease. Earlier single-arm phase 2 studies supported this strategy, demonstrating 12-week PFS rates of 57% with palbociclib and 74% with abemaciclib. However, randomized evidence confirming the benefit of CDK4 inhibition had been lacking prior to SARC041.

SARC041 Trial Design and Patient Population 

SARC041 (NCT04967521) was a randomized, double-blind, placebo-controlled phase 3 trial that enrolled 108 patients with recurrent or metastatic DDLPS. Patients were randomized 1:1 to receive abemaciclib 200 mg orally twice daily or placebo and were stratified by prior systemic therapy (none vs one or more prior lines). Importantly, patients assigned to placebo were permitted to cross over to open-label abemaciclib following disease progression, allowing evaluation of treatment activity after crossover while preserving patient access to the investigational therapy.

Efficacy Findings From SARC041 

The study demonstrated a significant improvement in PFS. Median PFS increased from 1.52 months with placebo to 9.67 months with abemaciclib (hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.25–0.59; P < .001), representing more than a six-fold improvement. 

Although the ORR was relatively modest at 9.3% compared with 0% for placebo, this finding aligns with the known mechanism of CDK4/6 inhibitors, which primarily induce cell-cycle arrest and therapy-induced senescence rather than rapid tumor regression. OS data remain immature. Median OS had not yet been reached in the abemaciclib arm compared with 25.45 months in the placebo arm (HR, 0.55; 95% CI, 0.28–1.07; P = .077), suggesting a favorable trend that did not yet reach statistical significance. Patients who crossed over to abemaciclib demonstrated a median PFS of 3.44 months and an ORR of 4.3%, confirming continued drug activity even after placebo progression. Importantly, grade 3 or higher adverse events (AEs) occurred at similar rates in both treatment arms, with no new safety signals identified (Figure 2).

Figure 2. Key Results from the SARC041 Trial

Dosing Considerations and Clinical Practice Implications 

One discussion generated by the trial involved dosing. Abemaciclib was administered at 200 mg twice daily, consistent with its approved monotherapy dose in breast cancer. During presentation of the trial, Mark Dickson, MD, of Memorial Sloan Kettering Cancer Center, explained that this dose was intentionally selected during study design. However, many clinicians recognize that fixed dosing of oral anticancer agents can be challenging in routine practice. Dose reductions are common, and many providers favor an individualized approach that begins with a lower dose and escalation as tolerated, particularly in older or frailer patients.

The placebo-controlled design also prompted considerable discussion. While an active comparator such as investigator’s choice chemotherapy (doxorubicin, trabectedin, or eribulin) may have reflected contemporary clinical practice, the placebo design allowed investigators to isolate the biologic activity of abemaciclib while permitting enrollment across multiple treatment settings, including treatment-naïve patients and those who had received several prior therapies. This flexibility is particularly valuable in rare diseases such as DDLPS, where patient accrual remains difficult.

Implications for Treatment Sequencing 

Perhaps the most clinically relevant question raised by SARC041 is how abemaciclib should be integrated into current treatment sequencing. Several clinical factors inform this decision. Anthracycline-based chemotherapy remains the preferred first-line option when rapid tumor shrinkage is required because of symptomatic disease, impending organ compromise, or bulky tumors. While single-agent doxorubicin produces ORRs of approximately 9% to 12%, the addition of ifosfamide increases response rates to approximately 13% to 15%, with some studies reporting responses approaching 20% to 22% in selected patients, albeit with substantially greater toxicity. Consequently, cytotoxic chemotherapy remains the treatment of choice when immediate cytoreduction is clinically necessary to provide relief of symptoms.

In contrast, CDK4/6 inhibition produces relatively modest tumor shrinkage (ORR 9.3%) but markedly prolongs PFS through induction of cell-cycle arrest and therapy-induced senescence rather than direct tumor cytotoxicity. This mechanism makes abemaciclib particularly attractive for patients with asymptomatic or slowly progressive disease, where durable disease stabilization may be more valuable than rapid tumor regression. For patients progressing after anthracycline therapy, abemaciclib represents a compelling alternative alongside eribulin and trabectedin. Likewise, elderly patients or those with significant comorbidities who are poor candidates for anthracycline-based chemotherapy may derive particular benefit from an oral targeted therapy with a favorable safety profile. Future subgroup analyses from SARC041 examining outcomes according to prior systemic therapy will further clarify the optimal placement of abemaciclib within the treatment algorithm.

In summary, SARC041 establishes abemaciclib as an active single-agent therapy with efficacy verified in a randomized trial for advanced DDLPS. Although OS data remain immature and are likely to be influenced by the trial’s crossover design, the substantial improvement in PFS, favorable toxicity profile, and strong biologic rationale support abemaciclib as an important new therapeutic option for patients with advanced DDLPS. The study represents a meaningful advance in a disease where effective systemic therapies have historically been limited and is likely to influence clinical practice pending incorporation into future treatment guidelines. Ongoing studies evaluating combination strategies, earlier versus later-line use, and perioperative applications will further define the role of CDK4/6 inhibition in the management of DDLPS.

References

1. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786-793. doi:10.1200/JCO.2015.62.4734
2. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomized, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629-1637. doi:10.1016/S0140-6736(15)01283-0
3. Livingston JA, Bugano D, Barbo A, et al. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of current treatment. Cancer. 2017;123(15):2911-2918. doi:10.1038/s41598-017-12132-w
4. Dickson MA, Schwartz GK, Keohan ML, et al. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol. 2016;2(7):937-940. doi:10.1001/jamaoncol.2016.0264
5. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4/6 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol. 2019;37(15_suppl):11006. doi:10.1200/JCO.2012.46.5476
6. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493-1501. doi:10.1016/S1470-2045(17)30624-1
7. D’Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomized, phase 2 trials. Lancet Oncol. 2018;19(3):416-426. doi:10.1016/S1470-2045(18)30006-8
8. Dickson MA, Ballman KV, Weiss MC, et al. SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. Presented at: American Society of Clinical Oncology Annual Meeting; 2026. Abstract LBA2
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Accessed June 16, 2026.
10. Italiano A, Toulmonde M, Cioffi A, et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and emerging targeted therapies. Curr Opin Oncol. 2023;35(4):312-319. doi:10.1093/annonc/mdr485